SIDE-BY-SIDE EVIDENCE
Compare evidence.
Keep the context.
Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.
Choose profilesSIDE-BY-SIDE EVIDENCE VIEW
Compare selected profiles
| Molecule |  Cardiogen | Vesugen | Pancragen |
|---|---|---|---|
| Research Topic | Clinical / Endocrine Pharmacology | Clinical / Endocrine Pharmacology | Clinical / Endocrine Pharmacology |
| Pharmacology | Experimental short peptide / cardiac tissue-culture research | KED tripeptide / experimental cell signalling | KEDW tetrapeptide / pancreatic research |
| PrimeCore Class | Class CExperimental / limited evidence | Class CExperimental / limited evidence | Class CExperimental / limited evidence |
| Evidence Grade | Grade EPreclinical evidence | Grade EPreclinical evidence | Grade DLimited / observational evidence |
| Evidence boundary | Cardiogen has preclinical myocardial-explant and animal data. Proliferation and p53 changes do not establish improved human cardiac function or survival. Supplier sequence, formulation and authorisation are unverified. It is not a substitute for evidence-based cardiac care. | Vesugen is KED, not KEDG or KEDW. Endothelial-cell, fibroblast and docking findings concern proliferation/differentiation markers. They do not establish prevention of stroke or heart attack, and human-derived cells are not human clinical trials. | Pancragen is KEDW, with terminal-form details requiring verification. A limited report included 30 healthy older adults and 33 people with type 2 diabetes; its abstract does not establish a randomised 63-person treatment trial. Biomarker and cell-differentiation findings do not justify replacing insulin or standard diabetes care. |
| Unknowns | Insufficient data in the current dataset | Insufficient data in the current dataset | Insufficient data in the current dataset |
| Limitations | English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language)
| English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language)
| English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language)
|
| Sources | |||
| Read more | Read English overview | Read English overview | Read English overview |
This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.
Choose another comparisonContinue reading
Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.
10 questions before drawing conclusions